Clinical trials: Gastrointestinal Reflux
GERD
Nexium RESPONSE Trial
The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.
- Trial name
- NCT00318968
- Testing
- Esomeprazole
- Where
- 38 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient…
- Trial name
- X842 (NCT07079540)
- Testing
- X842, Lansoprazole
- Where
- 53 sites in China
- Volunteers
- 380 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastroesophageal Reflux
LINX Reflux Management System Clinical Study Protocol
The purpose of the study is to evaluate the safety and effectiveness of the LINX Reflux Management System in the treatment of Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT00776997
- Testing
- Magnetic Sphincter Augmentation
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 100 people
- Sponsor
- Torax Medical Incorporated
Gastro Esophageal Reflux Disease
Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)
Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes.
- Trial name
- NCT01788085
- Testing
- Bravo pH monitoring procedure
- Where
- Israel
- Sponsor
- Medtronic - MITG
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Acid Reflux
A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers
A study to investigate the efficacy of ONO-8539 on acid-induced oesophageal hypersensitivity in healthy male adult volunteers.
- Trial name
- NCT01705275
- Testing
- ONO-8539
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastroesophageal Reflux Disease
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the…
- Trial name
- RESTORE500 (NCT07004439)
- Testing
- RefluxStop™ implantation
- Where
- 5 sites in Germany, Spain
- Volunteers
- 500 people
- Sponsor
- Implantica CE Reflux Ltd.
Reflux Esophagitis
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.
- Trial name
- NCT02477475
- Where
- 47 sites in Japan
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
Healthy
Efficacy of Dietary Supplement in Subjects With Acid Reflux and/or Abdominal Bloating/Distention and GI Symptoms
This study was a prospective randomized clinical study. There was interventional treatment for a total of 8 weeks including a 2-week washout period.
- Trial name
- NCT06808867
- Testing
- Dietary Supplement with Active Ingredient Blend
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Gastroesophageal Reflux
ASTERIX: Low Dose ASA and Nexium
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.
- Trial name
- NCT00251966
- Testing
- Esomeprazole
- Where
- 94 sites in Australia, Bulgaria and 9 more
- Volunteers
- 960 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT00365300
- Testing
- pantoprazole
- Where
- 38 sites in United States
- Volunteers
- 129 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00321737
- Testing
- Dexlansoprazole MR
- Where
- 98 sites in United States, Australia and 6 more
- Volunteers
- 445 people
- Sponsor
- Takeda
GERD
EndoStim Patient Registry
To provide a research tool enabling physicians to monitor long term clinical outcomes for patients undergoing gastroesophageal reflux disease (GERD) treatment with EndoStim LES Stimulation System.
- Trial name
- RESTORE (NCT02441400)
- Testing
- EndoStim LES Stimulation System
- Where
- 30 sites in Argentina, Austria and 5 more
- Volunteers
- 350 people
- Sponsor
- EndoStim Inc.
Gastroesophageal Reflux Disease
The Use of International GerdQ Questionnaire
There are three main directions for use GerdQ in practice. First of all, GerdQ can be used to diagnose GERD with an accuracy comparable to the accuracy of diagnosis of GERD by the specialist (gastroenterologist).
- Trial name
- GERDq (NCT01489735)
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
The purpose of this trial is to investigate the pharmacodynamic effect on reflux parameters of SPD557 tablets (0.5 mg t.i.d., on top of PPI treatment) in patients with Gastroesophageal Reflux Disease (GERD) with persistent…
- Trial name
- NCT01370863
- Testing
- SPD557
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 67 people
- Sponsor
- Shire
Gastroesophageal Reflux Disease
A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients
To investigate the safety of C13-CAC and the relationship among C13-CAC breath test, gastric pH, and the improvement of symptoms by switching PPI in PPI resistant GERD patients
- Trial name
- NCT03284177
- Testing
- Calcium (13C)Carbonate, Gastric acid inhibitors, Gastric pH monitoring
- Where
- 13 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastroesophageal Reflux
Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy
This observational study aims to explore the effectiveness of hydrotalcite, marketed as Talcid, in alleviating acid-related symptoms that occur due to an acid rebound after discontinuing a non-/no-longer-indicated long-term…
- Trial name
- NCT07291700
- Testing
- Hydrotalcite (Talcid, BAYX002833)
- Where
- 2 sites in Germany
- Volunteers
- 167 people
- Sponsor
- Bayer